ALB and neoplasm with perivascular epithelioid cell differentiation: Nab-Sirolimus, an albumin-bound nanoparticle sirolimus formulation that inhibits mammalian [mechanistic] targets of rapamycin (mToR), achieved FDA approval for the treatment of malignant perivascular epithelioid cell tumors (PEComa) based on positive results from the phase II, single-arm, registration trial AMPECT, NCT02494570 [47].